Il 2 il 12

Manufactured by R&D Systems

IL-2/IL-12 is a laboratory product that functions as a recombinant human cytokine. It is commonly used in research applications.

Automatically generated - may contain errors

Lab products found in correlation

Dynabeads mouse t activator cd3 cd28 for t cell expansion and activation, by Thermo Fisher Scientific (1 mentions) Dynabeads untouched mouse cd8 cells kit, by Thermo Fisher Scientific (1 mentions) Dynabeads untouched mouse cells kits, by Thermo Fisher Scientific (1 mentions) Il 36β, by R&D Systems (1 mentions) Interleukin 2 (il 2), by Roche (1 mentions) Agilent bioanalyzer, by Agilent Technologies (1 mentions) Rnaeasy mini extraction kit, by Qiagen (1 mentions)

Spelling variants of this product

IL-12 (213 citations) IL-12 and IL-2 recombinant proteins (2 citations)

2 protocols using il 2 il 12

Murine T Cell Activation and Differentiation

Check if the same lab product or an alternative is used in the 5 most similar protocols

For in vitro cultures, naïve CD3⁺, CD4⁺, CD8⁺ T cells from spleen and lymph nodes (inguinal, brachial, axillary and cervical) of male and female C57BL/6J mice (6–9 weeks old) were purified by negative selection using Dynabeads™ Untouched™ Mouse Cells Kits from ThermoFisher Scientific (Waltham, MA). Cells were then differentiated in vitro using Dynabeads™ Mouse T-Activator CD3/CD28 for T cell Expansion and Activation from ThermoFisher Scientific (1:1 ratio) (Waltham, MA), plus hrIL-2 (30 U/ml), in the presence or absence of NAM 30 mM or 10 mM. After 66 h live cells were recovered using Lympholyte®-M from Cederlane (Burlington, NC) as per manufacturer’s instructions. Lastly, cells were restimulated using either Dynabeads™ Mouse T-Activator CD3/CD28 or PMA + ionomicyn (PMAi). For ex-vivo cultures, in vivo–primed CD8⁺ T cells from spleen and lymph nodes (inguinal, brachial, axillary and cervical) were purified by negative selection using Dynabeads™ Untouched™ Mouse CD8 Cells Kit from ThermoFisher Scientific (Waltham, MA) following biotinylated α-CD45.2 Ab from ThermoFisher Scientific (Waltham, MA). Cells were then restimulated using SIINFEKL, PMAi or IL-2/IL-12 plus IL-33 or IL-36β (R&D Systems, Minneapolis, MN) for the indicated time points.

Agliano F., Karginov T.A., Ménoret A., Provatas A, & Vella A.T. (2022). Nicotinamide breaks effector CD8 T cell responses by targeting mTOR signaling. iScience, 25(3), 103932.

+ Open protocol

+ Expand

Quantifying Tumor-Specific T-Cell Responses

Check if the same lab product or an alternative is used in the 5 most similar protocols

To evaluate Granzyme B mRNA expression, spontaneous tumors were obtained from the mice 21 days after the infusions of neu p98 specific and naïve T-cells. Total RNA was extracted from the expanded T-cells using a RNA Easy Mini Extraction Kit (Qiagen, Valencia, CA) and the integrity of the RNA was confirmed using an Agilent BioAnalyzer (Foster City, CA). cDNA synthesis and real-time RT-PCR were performed as previously described (13 (link)) using primer and probes from Applied Biosystems (Carlsbad, CA). The levels of Granzyme B mRNA expression were normalized to b-actin using the delta Ct method (13 (link)).
To evaluate Th1/Th17 gene expression, CMV specific human T cells were expanded ex vivo with the different cytokine conditions of IL-2 (Hoffman-La Roche), IL-2/IL-12 (R&D System, Minneapolis, MN), and IL-2/IL-21 (Peprotech) using previously published methods (14 (link)). Total RNA was extracted and real-time RT-PCR was performed as above. The levels of mRNA expression of Th1/Th17 cytokine (IFN-gamma, TNF-alpha, IL-17, IL-21) and Th17-differentiation genes RORc and IFN-gamma regulatory gene IRF-4 were normalized to b-actin.

Phan-Lai V., Dang Y., Gad E., Childs J, & Disis M.L. (2015). The anti-tumor efficacy of IL-2/IL-21-cultured polyfunctional neu-specific T-cells is TNF-alpha/IL-17 dependent. Clinical cancer research : an official journal of the American Association for Cancer Research, 22(9), 2207-2216.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!